A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 2

Conditions

Hepatitis C

Treatments

Drug: Comparator: Placebo
Drug: Ribavirin
Drug: Vaniprevir
Drug: Pegylated Interferon (peg-IFN)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00880763
2009_576
7009-016

Details and patient eligibility

About

The study evaluates safety and efficacy of vaniprevir (MK7009), when administered with Pegylated-Interferon (peg-IFN) and Ribavirin, in Japanese patients with Hepatitis C infection. The primary hypotheses are that 1.) the proportion of patients achieving rapid viral response (RVR) in one or more of the vaniprevir treatment groups is superior to that in the placebo group, when each is administered concomitantly with pegylated interferon (peg-IFN) α-2a and ribavirin; and 2.) vaniprevir at the studied doses is well tolerated compared with placebo, when each is administered concomitantly with peg-IFN α-2a and ribavirin for 28 days.

Enrollment

90 patients

Sex

All

Ages

20 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Has chronic genotype 1 Hepatitis C infection

Exclusion criteria

  • Has not tolerated previous course of peg-IFN and ribavirin
  • Has HIV
  • Has Hepatitis B
  • Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and ribavirin

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

90 participants in 4 patient groups, including a placebo group

Vaniprevir 200 mg + peg-IFN + ribavirin
Experimental group
Description:
Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
Treatment:
Drug: Pegylated Interferon (peg-IFN)
Drug: Vaniprevir
Drug: Ribavirin
Vaniprevir 600 mg + peg-IFN + ribavirin
Experimental group
Description:
Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
Treatment:
Drug: Pegylated Interferon (peg-IFN)
Drug: Vaniprevir
Drug: Ribavirin
Vaniprevir 1200 mg + peg-IFN + ribavirin
Experimental group
Description:
Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
Treatment:
Drug: Pegylated Interferon (peg-IFN)
Drug: Vaniprevir
Drug: Ribavirin
Placebo + peg-IFN + ribavirin
Placebo Comparator group
Description:
Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
Treatment:
Drug: Pegylated Interferon (peg-IFN)
Drug: Ribavirin
Drug: Comparator: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems